Fidelity SPDR Advertisement
Home > Boards > US OTC > Delisted >

Immune Network Ltd (fka IMMFF)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Moderator: lifegear
Search This Board:
Last Post: 1/17/2013 9:42:28 AM - Followers: 1 - Board type: Free - Posts Today: 0
IMMFF -- Immune Network Ltd. Address: 2906 West Broadway Suite 365 Vancouver, BC V6K 2G8 CAN Immune Network Ltd. is a biotechnology company focused on the development of new drugs to treat major diseases predominantly involving the body's immune system. The Company's projects include Alzheimer Project AD2 and AIDS Project 1F7 and hNM01, including Hepatitis C Monoclonal Antibodies. During the year ended December 31, 2001, Immune Network suspended various projects due, in part, to fiscal constraints and for commercial reasons, although it has retained an interest in some of the projects by way of royalties in future revenues, if any. Suspended projects include Asthma Project BP1, Eczema Project BP1249, Cancer Project Viraplex, and Herpes Cold Sore Project Zorex. Website: http://www.immunenetwork.com Phone: 604-781-9094 Primary State of Incorporation: British Columbia Country of Incorporation: CANADA Officers: Allen Bain, President/CEO; Mark Glusing, COO/CFO/Secretary Outstanding Shares: 19,810,890 as of 2002-07-17 Current Capital Change: shs decreased by 1 for 10 split Ex-Date: Record Date: Pay Date: 2002-07-29 Company Notes: Formerly=Immune Network Research Ltd. until 8-00 Transfer Agent: Computershare Trust Company of Canada Inc., Vancouver, BC V6C 3B9 Immune Network's Phase 2 clinical trial results in Alzheimer’s disease. Preliminary evidence suggests that certain nano-pharmaceutical formulations may improve the potency and safety of dapsone for Alzheimer’s disease, an existing drug which is FDA-approved for other indications. Immune Network to Tackle Diabetes Market Wire, January, 2006 Immune Network Ltd. (OTC: IMMFF) advises that it has acquired an 85% interest in B.C.-based Dr Nature Health Products Inc. -- which has a breakthrough natural health product, DRN 11, that is proven clinically beneficial in the management of diabetes -- in exchange for 7.5 million Immune Network shares. Immune will now commence marketing DRN 11, the flagship product developed by Dr Nature over the past eight years. Completed regulatory filing for DRN 11 in Canada allows the Company to commence sales immediately. Sales into the U.S. and other markets will also be pursued. Pre-clinical studies have demonstrated that DRN 11 sensitizes the body's response to its own insulin making it work more efficiently (by increasing insulin binding and internalization). As a result of better utilization of insulin, muscle cell glucose uptake is increased. The significant clinical benefits against all diabetes symptoms and complications have been demonstrated through three DRN 11 clinical studies. DRN 11 is an excellent supplement compound that can be used alongside prescription medications such as the US$800 million drug Metformin. In the DRN 11 clinical studies, reductions in the range of 15-20% in blood sugar levels have complemented a noted quality of life benefit with no side effects and an overall improvement in the well being and general health of the study participants. Diabetes is the third leading cause of death in the United States with an economic cost of over $100 billion per year and affecting 18.2 million people with an estimated 15 million not yet diagnosed. Safe Harbor Statement The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially. For further information contact: Dr. Allen Bain 1-650-241-1888 Email Contact WEEKLY
PostSubject
#22   IMMFF revoked: Renee 01/17/13 09:42:28 AM
#21   IMMFF: SEC Suspension: Renee 12/20/12 09:38:10 AM
#20   Does any one knows how many millions o/s thedog 07/08/11 09:01:47 AM
#19   Immunitor Publishes Interim Data From Phase IIb imm01 ragmuff 12/30/10 09:23:46 AM
#18   100 billion annual world market! hdsstocks 11/29/10 09:29:54 AM
#17   wheres the news! hdsstocks 11/29/10 09:29:09 AM
#16   ,,,,,,I think today's news good for a few pence--MONEYMADE Cesare Borgia 11/29/10 09:27:08 AM
#15   first they have to make the SEC filing, thedog 09/23/10 02:20:47 AM
#14   Thanks lifegear! Nothing seems to move this originunknown 02/13/07 10:04:20 PM
#13   NEWS TODAY: Immune Network to Farm in on lifegear 02/13/07 06:20:24 PM
#12   19M or less ... only problem is no originunknown 09/10/06 01:21:18 PM
#11   I think the float is really tiny lifegear 09/10/06 12:53:54 PM
#10   Either they don't want to spend the money originunknown 09/10/06 12:44:37 PM
#9   but the acquisition was just Jan 2006...they don't lifegear 09/10/06 12:41:17 PM
#8   Virtually no trading volume to speak of ... originunknown 09/10/06 08:03:03 AM
#7   Website news goes back to 2003 .. hope originunknown 09/10/06 07:59:57 AM
#6   Immune Network Ltd. is a biotechnology company focused lifegear 09/09/06 09:54:56 PM
#5   I found it...85% acquisition lifegear 09/09/06 09:51:26 PM
#4   maybe it's time to add some more....I thought lifegear 09/09/06 09:47:51 PM
#3   sure hope so .. maybe a little ACTC originunknown 09/09/06 09:29:24 PM
#2   me too...it's about time something happens to this lifegear 09/09/06 08:56:11 PM
#1   I have owned some of this for years originunknown 09/09/06 05:37:50 PM
PostSubject